Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TherVacB - A Multi-center Phase 1b/2a Trial to Assess Safety, Tolerability and Immunogenicity of a Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

NCT06513286 is registered in ClinicalTrials.gov with Michael Hoelscher as lead sponsor.

NCT NCT06513286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06513286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TherVacB - A Multi-center Phase 1b/2a Trial to Assess Safety, Tolerability and Immunogenicity of a Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
Lead sponsor
Michael Hoelscher
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 12, 2025
Completion date
December 31, 2026
Enrollment
81 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b